Brief: Axovant Posts Q2 Loss Per Share $0.61

Sio Gene Therapies

08/11/2019 13:24

Nov 8 (Reuters) - Axovant Gene Therapies Ltd  AXGT.O :
    * AXOVANT ANNOUNCES CORPORATE UPDATES AND FINANCIAL RESULTS
FOR
SECOND FISCAL QUARTER ENDED SEPTEMBER 30, 2019
    * Q2 LOSS PER SHARE $0.61
    * Q2 EARNINGS PER SHARE ESTIMATE $-1.09 -- REFINITIV IBES
DATA
    * AS OF SEPTEMBER 30, 2019, WE HAD $60.3 MILLION OF CASH AND
CASH
EQUIVALENTS
    * AXOVANT -  EXPECTS TO PRESENT 3-MONTH DATA FROM SECOND
DOSE
COHORT OF SUNRISE-PD PHASE 2 STUDY OF AXO-LENTI-PD IN H1 2020
    * AXOVANT - EXPECTS TO INITIATE A RANDOMIZED,
SHAM-CONTROLLED
STUDY OF AXO-LENTI-PD BY END OF CALENDAR YEAR 2020

Source text for Eikon:  ID:nGNX1gLQQK 
Further company coverage:  AXGT.O 

 ((Briefs@thomsonreuters.com;))